Cite

HARVARD Citation

    Xu, H. et al. (2020). Crizotinib vs platinum‐based chemotherapy as first‐line treatment for advanced non‐small cell lung cancer with different ROS1 fusion variants. Cancer medicine. pp. 3328-3336. [Online]. 
  
Back to record